Scythian Biosciences Corp. (TSXV: $SCYB.V)
Retains Hybrid Financial Ltd. for Investor Relations Activities
TORONTO
- August 17, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (the
"Company") (TSXV: SCYB) announces that it has retained the
services of Hybrid Financial Ltd. ("Hybrid Financial") for strategic
investor relations activities. The initiatives includes marketing and investor
relations services for the Company.
About Scythian Biosciences Corp.
Scythian
is a research and development company committed to finding a solution for the
prevention and treatment of concussions and traumatic brain injury with its
proprietary Cannabinoid combination.
Scythian's
mission is to be the first accepted drug regimen for concussive treatment.
Scythian has recently formed a collaboration with the University of Miami and
its world renowned neuroscientific team to conduct pre-clinical and clinical
trials of its drug regimen. The University of Miami believes that Scythian's
scientific approach shows significant promise and differs from previous
approaches to treat this growing problem. The collaboration with the University
of Miami allows access to their extensive knowledge base in the fields of
traumatic brain injury and concussions and allows for Scythian's clinical
studies to be undertaken at their world-class facilities.
Gillian
A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr.
Hotz is a nationally recognized behavioral neuroscientist and expert in
neurotrauma, concussion management, and neurorehabilitation. She has extensive
experience in neurocognitive testing. Dr. Hotz has been the co-director of
University of Miami Miller School of Medicine's Concussion Program since 1995.
Scythian
is also endorsed by Pro Football Legends and the World Boxing Association on
its mission.
is
a Featured biotech and marijuana company on Investorideas.com
Disclaimer/Disclosure: Investorideas.com
is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian
Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis
Investor Ideas Directory and is a paid featured cannabis company and biotech
for news, social media and PR effective August 7th for 2 months. More details
- http://www.investorideas.com/About/News/Clientspecifics.asp
Additional
info regarding BC Residents and global Investors: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
No comments:
Post a Comment